Key facts
- Arthrosi Therapeutics’s last known valuation is $1.5B (Dec 2025).
- It has raised $298.8M across 7 recorded rounds; the latest was Later Stage VC ($60.9M) in Jun 2025.
- Notable investors include Heda Ventures, Viva BioInnovator, JMCR Family Office, Highlight Capital Partners, LTS Capital Advisors — 16 tracked in total.
- Arthrosi Therapeutics has filed 8 Form Ds with the SEC since 2018, most recently Jun 2025 ($60.9M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Arthrosi Therapeutics
Funding rounds
7 roundsAbout Arthrosi Therapeutics
Developer of biotechnology drugs designed to reduce flare and tophi in gout patients. The company provides clinical-stage research and development services focused on therapy for gout and chronic kidney disease, enabling medical professionals to provide strong uric acid reduction and the resolution of joint damage caused by tophi.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Employees
- 36
- Website
- arthrosi.com/
- Ownership
- Privately Held (backing)
Arthrosi Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arthrosi Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arthrosi Therapeutics in its N-PORT filings yet. We sweep new filings monthly.